This literature review presents an inventory of the nature and incidence of side-effects that arise from the clinical application of monoclonal antibodies (MoAb) for the diagnosis and treatment of cancer. Most side-effects occurred during therapy. Toxic reactions, such as fever, sweating and chills, were more common than immunological skin reactions; they were observed predominantly in association with the elimination of circulating target cells. Dosage and rate of administration of the MoAb appeared to have little influence on the reactions, which disappeared quickly and did not necessitate discontinuation of treatment. Serum sickness, anaphylactic reactions and bronchospasms were not common; the patients reacted quickly to the indicated therapy. Prevention of the side-effects described here, especially during diagnostic applications, was such that they need not form a barrier to the clinical use of MoAb.
KöhlerG., MilsteinC.Continuous cultures of fused cells secreting of predefined specificity.Nature1975; 256: 495–7.
2.
AllumW.H., MacdonaldF., FieldingJ.W.L.Monoclonal antibodies in the diagnosis and treatment of malignant conditions.Surg Ann1986; 18: 41–64.
3.
PauwelsE.K.J., CletonF.J., OsantoS.Scintigrafisch onderzoek bij de opsporing van kanker met behulp van tegen de tumor gerichte monoklonale antistoffen.Ned Tijdschr Geneeskd1984; 128: 805–9.
4.
MillerR.A., MaloneyD.G., WarnkeR., LevyR.Treatment of B-cell lymphoma with monoclonal-anti-idiotype antibody.N Engl J Med1981; 306: 517–22.
5.
SearsH.F., HerlynD., SteplewskiZ., KoprowskiH.Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma.J Biol Resp Med1984; 3: 138–50.
6.
LenhardREJr, OrderS.E., SpunbergJ.J., AsbelS.O., LeibelS.A.Isotopic immunoglobulin: A new systemic therapy for advanced Hodgkin's disease.J Clin Oncol1985; 3: 1296–300.
7.
MeekerT.C., LowderJ.N., MaloneyD.G.. A clinical trial of anti-idiotype therapy for B-cell malignancy.Blood1985; 65: 1349–63.
8.
DouillardJ.Y., Le MevelB., CurtetC., VignoudJ., ChatelJ.F., KoprowskiH.Immunotherapy of gastrointestinal cancer with monoclonal antibody.Med Oncol & Tumor Pharmacother1986; 3: 141–6.
9.
FrödinJ.E., BiberfeldP., ChristenssonB.. Treatment of patients with metastasizing colorectal carcinoma with mouse monoclonal antibodies (MoAb 17-1A). A progress report.Hybridoma1986; 5: 151–61.
10.
DillmanR.O., BeauregardJ.C., HalpernS.E., ClutterM.Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies.Biol Response Mod1986; 5: 73–84.
11.
LowderJ.N.The current state of monoclonal antibodies in the diagnosis and therapy of cancer. In: Hickey RC, ed.Current problems in cancer,1986; 10: 485–551.
12.
RitzJ., PesandoJ.M., SallanS.E.. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody.Blood1981; 58: 141–52.
13.
FoonK.A., SchroffR.W., MayerD., SherwinS.A., OldhamR.K.Monoclonal antibody therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma: preliminary observations. In: BossB.D., LangmanR., eds. Monoclonal antibodies and cancer.Orlando, New York: Academic Press Inc, 1983; 39–52.
14.
DillmanR.O., ShawlerD.L., DillmanJ.B., RoystonI.Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody.J Clin Oncol1984; 2: 881–91.
15.
FoonK.A., SchroffR.W., BunnP.A.. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia.Blood1984; 64: 1085–93.
16.
BallE.D., BernierG.M., CornwellG.G.III, McIntyreO.R., O'DonnellJ.F., FangerM.W.Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia.Blood1983; 62: 1203–10.
17.
RoittI.M., BrostoffJ., MaleD.K.Immunology.Gower Medical Publishing, Churchill Livingstone London,1985; 20: 4.
18.
SearsH.F., HerlynD., SteplewskiZ., KoprowskiH.Phase-II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma.Cancer Res1985; 45: 5910–3.
19.
LobuglioA.F., SalehM., PetersonL.. Phase I clinical trial of CO17-1A monoclonal antibody.Hybridoma1985; 5: 117–23.
20.
LemkinS., TokitaK., ShermanG.. Phase III study of monoclonal antibodies (MCA) in gastrointestinal cancer.Proc Am Soc Clin Oncol1984; 3: 47. (C-181).
21.
OldhamR.K., FoonK.A., MorganA.L.. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration.J Clin Oncol1984; 2: 1235–44.
22.
SearsH.F., HerlynD., SteplewskiZ., KoprowiskiH.Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma.Hybridoma1986; 5: 109–15.
23.
DillmanR.O., ShawlerD.L., SobolR.E.. Murine MoAb therapy in two patients with chronic lymphocytic leukemia.Blood1982; 59: 1036–45.
24.
LashfordL., JonesD., PitchardJ., GordonI., BreatnachF., KemsheadJ.T.Therapeutic application of radiolabelled monoclonal antibody UJ 13A in children with disseminated neuroblastoma.Cancer Drug Deliv1985; 2: 233.
DillmanR.O., BeauregardJ.C., HalpernS.P., SobolR.S., RoystonI.Association between disappearance of circulating target cells and toxicity during murine monoclonal antibody infusions.Clin Res1983; 31: 405a.
27.
MillerR.A., MaloneyD.G., McKillopJ., LevyR.In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia.Blood1981; 58: 78–86.
28.
EngelstadB.L., SpitlerL.E., Del RioM.J.. Phase-I immunolymphoscintigraphy with an In-111-labeled antimelanoma monoclonal antibody.Radiology1986; 161: 419–22.
29.
KeenanA.M., WeinsteinJ.N., MulshineJ.L.. Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of Indium-111-labeled T101 monoclonal antibody.J Nucl Med1987; 28: 42–6.
30.
NelpW.B., EaryJ.F., HellströmK.E.. Preliminary studies of monoclonal antibody lymphoscintigraphy in malignant melanoma.J Nucl Med1987; 28: 34–41.
31.
LotzeM.T., CarrasquilloJ.N., WeinsteinJ.N.. Monoclonal antibody imaging of human melanoma.Ann Surg1986; 204: 223–35.
32.
CarrasquilloJ.A., KrohnK.A., BeaumierP.. Diagnosis and therapy for solid tumors with radiolabeled antibodies and immune fragments.Cancer Treat Resp1984; 68: 317–28.
33.
OldhamR.K., FoonA.F., MorganC.. Monoclonal antibody therapy of malignant melanoma in vivo localization in cutaneuos metastasis after intravenous administration.J Clin Oncol1984; 2: 1235–44.
34.
CarrasquilloJ.A., LarsonS.M., HellströmK.E., HellströmI.Radioimmunodetection of human melanoma with monoclonal antibodies and Fab fragments. In: BuchielS.W., RhodesB.A., eds. Radioimmunoimaging and radioimmunotherapy.New York: Elsevier Publishing Co., 1983; 197.
35.
LarsonS.M., BrownJ.P., WrightP.W., CarrasquilloJ.A., HellströmI., HellströmK.E.Imaging of melanoma with I-131-labeled monoclonal antibodies.J Nucl Med1983; 24: 123–9.
36.
GoodmanG.E., BeaumierP., HellströmI., FernyhoughB., HellströmK.E.Pilot trial of murine monoclonal antibodies in patients with advanced melanoma.J Clin Oncol1985; 3: 340–52.
37.
HalpernS.E., DillmanR.O., WitztumK.F.. Radioimmunodetection of melanoma utilizing In-111 96.5 monoclonal antibody: A preliminary report.Radiology1985; 155: 493–9.
38.
HoughtonA.N., MintzerD., Cordon-CardoC.. Mouse monoclonal IgG3 antibody detecting G103 ganglioside: A phase I trial in patients with malignant melanoma.Proc Natl Acad Sci USA1985; 82: 1242–6.
39.
MurrayJ.L., RosenblumM.G., SobolR.E.. Radioimmunoimaging in malignant melanoma with In-111-labeled monoclonal antibody 96.5.Cancer Res1985; 45: 2376–81.
40.
BiersackH.J., BockischA., OehrP.. Clinical results of immunoscintigraphy in a variety of malignant tumors with special reference to immunohistochemistry.Nuklearmedizin1986; 25: 167–71.
41.
BuraggiG.L.Radioimmunodetection of malignant melanoma with the 225.28S monoclonal antibody to HMW-MAA.Nucl Med1986; 25: 220–4.
42.
MurrayJ.L., RosenblumM.G., LamkiL.. Clinical parameters related to optimal tumor localization of Indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018.J Nucl Med1987; 28: 25–33.
43.
SobolR.E., DillmanR.O., SmithJ.D.. Phase I evaluation of murine monoclonal-anti-melanoma antibody in man: Preliminary observations. In: Mitchell MS, Oettgen HF, eds. Hybridomas in cancer diagnosis and treatment. Progress in cancer research and therapy, Vol. 21.New York: Raven Press,1982; XVIII: 264.
44.
MachJ.P., ChatalJ.F., LumbrosoJ.D.. Tumor localization in patients by radiolabeled monoclonal antibodies against colonca.Cancer Research1983; 43: 5593–600.
45.
EpenetosA.A., MatherS., GranowskaM.. Targeting of Iodine-123-labeled tumour-associated monoclonal antibodies to ovarian, breast and gastrointestinal tumours.Lancet1982; 2: 999–1006.
46.
FarrandsP.A., PimmM.V., EmbletonM.J.. Radioimmunodetection of human colorectal cancers by an antitumor monoclonal antibody.Lancet1982; 2: 397–400.
47.
EpenetosA., SnookD., DurbinM., JohnsonP.M., Taylor-PapadimitriouJ.Limitations of radiolabeled monoclonal antibodies for localization of human neoplasm.Cancer Res1986; 46: 3183–91.
48.
SmedleyH.M., FihanP., LennoxE.S.. Localisation of metastatic carcinoma by a radiolabelled monoclonal antibody.Br J Cancer1983; 47: 253–9.
49.
SteplewskiZ., SearsH.F., KoprowskiH.Monoclonal antibody infusion in gastrointestinal cancer patients. In: Herfath CH, Schlag P, Hohenberger P, eds. Recent results in cancer research. Therapeutic strategies in primary and metastatic liver cancer.Berlin-Heidelberg: Springer-Verlag,1986; 100: 321–3.
50.
EstebanJ.M., ColcherD., SugarbakerP.. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered monoclonal antibody B72.3.Int J Cancer1987; 39: 50–9.
51.
RainsburyR.M., WestwoodJ.H., CoombesR.C.. Location of metastatic breast carcinoma by a monoclonal antibody chelate labeled with Indium-111.Lancet1983; 2: 934–8.
52.
CascinelliN., DociR., BelliF.. Evaluation of toxic effects following administration of monoclonal antibody MBrl in patients with breast cancer.Tumori1986; 72: 267–72.
53.
ChanS.Y.T., EvanG.I., RitsonA., WatsonJ., WraightP., SikoraK.Localization of lung cancer by a radiolabelled monoclonal antibody against the C-myc oncogene product.Br J Cancer1986; 54: 761–9.
54.
CarrasquilloJ.W., BunnPAJr., KeenanA.M.. Radioimmunodetection of cutaneuos T-cell lymphoma with 111 In-labeled T101 monoclonal antibodies.N Engl J Med1986; 315: 673–80.
55.
CarrasquilloJ.A., MulshineJ.L., BunnPAJr.. Indium-111 T101 monoclonal antibody is superior to Iodine-131 T101 in imaging of cutaneous T-cell lymphoma.J Nucl Med1987; 28: 281–7.
56.
MiraldiF., StrandjordS., CocciaP.. Imaging neuroblastoma in patients with radiolabeled monoclonal antibodies as a basis for targeting therapy.Proc ASCO1985; 4: 219.
57.
MarkhamN., RitsonA., JamesO.. Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody.J Hepatol1986; 2: 25–31.
58.
SindelarW.F., MaherM.M., HerlynD., SearsH.F., SteplewskiZ., KoprowskiH.Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma. Preliminary results.Hybridoma1986; 5: 125–32.
59.
VerrillH., GoldbergM., RosenbaumR.. Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma. A preliminary report.Hybridoma1986; 5: 175–83.
60.
DillmanR.O., BeauregardJ.C., ShawlerD.L., SobolR.E., RoystonI.Results of early trials using murine monoclonal antibodies as anticancer therapy. In: PeetersH., ed. Protides of the biological fluids. Proceedings of the thirtieth colloquiem, Bruges, Amsterdam: Elsevier Publishing Co., 1982; 353–8.
SchroffR.W., FarrellM.M., KleinK.A., OldhamR.K., FoonK.A.T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients.J Immunol1984; 133: 1641–8.
63.
CapelP.J.A., PreijersFWMB, AllebesW.A., HaanenC.Treatment of chronic lymphocytic leukemia with monoclonal anti-idiotypic antibody.Neth J Med1985; 28: 112–8.
64.
DillmanR.O., BeauregardJ., ShawlerD.L.. Clinical trial of 24 hour infusions of T101 murine monoclonal antibodies. In: ReisfeldR.A., StewardS., eds. Monoclonal antibodies and cancer therapy. Proceedings of the Roche-UCLA Symposium, 1985: 133–46.
65.
MillerR.A., LevyR.Response of cutaneous T-cell lymphoma to therapy with hybridoma monoclonal antibody.Lancet1981; 2: 226–30.
MillerR.A., OseroffA.R., StratteP.T., LevyR.Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma.Blood1983; 62: 988–95.
68.
NadlerL.M., StashenkoP., HardyR.. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.Cancer Res1980; 40: 3147–54.
69.
PressO.W., AppelbaumF., LedbetterJ.A.. Monoclonal antibody 1F5 (anti-CD 20) serotherapy of human B cell lymphomas.Blood1987; 69: 584–91.
70.
GiardinaS.L., SchroffR.W., KippsT.J.. The generation of monoclonal anti-idiotype antibodies to human B cell-derived leukemias and lymphomas.J Immunol1985; 135: 653–8.
71.
LowderJ., CarciaC., MeekerT., WarnkeR., LevyR.Therapy of B-lymphocytic lymphoma with murine monoclonal anti-idiotype antibodies: correlation of response with host T cell infiltrate of tumor.Proc ASCO1985; 4: 209. (C-817).
72.
RankinE.M., HekmanA., SomersR., Ten Bokkel HuininkW.Treatment of two patients with B-cell lymphoma with Mo-anti-idiotype Abs.Blood1985; 65: 1373–81.
73.
DillmanR.O., RoystonI.Applications of monoclonal antibodies in cancer therapy.Br Med Bulletin1984; 40: 240–6.
74.
BadgerC.C., BernsteinI.D.. Prospects for monoclonal antibody therapy of leukemia and lymphoma.Cancer1986; 58(2 suppl): 584–9.
75.
FoonK.A., SchroffR.W., BunnPAJr.. Clinical applications of monoclonal antibodies for patients with leukemia and lymphoma.Prog Clin Biol Res1986; 211: 265–84.
